Axe Compute Inc. Q2 FY2023 earnings call

• Continued pipeline growth with biotech, biopharma, and research institutions integrating AI/ML into drug discovery. - Pedal platform details: over 150,000 heterogeneous tumor samples, over 200,000 pathology slides, and CLIA-certified AtLab. - Partnerships: CRH for genomic-based precision radiation therapy, Flu gen on respiratory disease vaccine, Integra Therapeutics on gene therapies. - Added Dr. Bernard A. Harris, Jr. and Andrew Einhorn to Business Advisory Board. - Moved corporate headquarters to Pittsburgh, PA, a life sciences hub.

In Q2 2023, Predictive Oncology recorded revenue of $490,110, compared to $371,591 in Q2 2022. Gross margin was 67% in Q2 2023 versus 64% in Q2 2022. Operating expenses were under $1 million in Q2 2023 compared to $900,000 in Q2 2022. Cash and cash equivalents were $14.8 million at the end of Q2 2023, down from $22.1 million at Dec 31, 2022. Stockholders' equity stood at $14.7 million at Q2 2023 end, versus $21.8 million at Dec 31, 2022.

• Aim to achieve breakeven on operations by the end of 2024 or sooner, depending on contract revenue and approval timelines. - Anticipate more collaborations and partnerships in the coming quarters.

• Substantial risks and uncertainties in forward-looking statements, including factors in SEC filings. - Concerns about cash burn and potential need for additional financing.

Q: Concern about cash burn rate, breakeven timeline, and warrants exercisability.

A: Bob Myers stated cash burn rate is consistent, aiming to extend runway via revenue and maintaining cash levels; warrants have a lowest price of $14.

Q: Potential timeline for EPS breakeven.

A: Pamela Bush mentioned goal to breakeven by end of 2024 or sooner, depending on contract progress.